Woman took MS drug for five and a half weeks; during research drug had been linked to diminished white cell count, sometimes linked to low immunity
Although drug manufacturer Biogen says they believe a 59 year old woman’s death from taking their MS drug Tecfidera (dimethyl fumarate, or BG-12) is unlikely, they continue to investigate.
Tecfidera was approved by the FDA in March for to treat patients suffering periodic attacks of MS symptoms.
According to the Wall Street Journal:
“The unidentified woman had taken Tecfidera for 5½ weeks before side effects like nausea, vomiting and diarrhea prompted her to stop taking the drug, according to the spokeswoman. The woman had a history of irritable bowel disease and recurring infections including bronchitis” according to a Biogen spokeswoman. During initial studies of the drug prior to approval, a decrease in white blood cell count that staves infection was noted as a side effect, among others including nausea, diarrhea and vomiting.
The Journal reports some doctors are reverting to other MS drug treatments until the investigation of this drug is complete.
“Biogen Idec is committed to patient safety, and it continues to be our first priority,” a spokeswoman told the the Wall Street Journal.
Harman Law LLC is currently investigating deaths and serious injuries related to Tecfidera.
If you have experienced serious side effects or know someone who has died while taking or after taking the MS drug Tecfidera, contact the dangerous drug attorneys at Harman Law LLC to learn your legal rights and eligibility for compensation. We offer a no cost, no obligation initial consultation to patients and families of patients. Call 1-888-55-HARMAN or fill out the “Quick Connect” form at the top right of this page.
Posted on behalf of
